



# Unique Test Menu for Rapid Patient Triage in the ED

Critical Care Tests Available:

pH

PCO<sub>2</sub>

PO<sub>2</sub>

SO<sub>2</sub>

Hct

Hb

iMg

Na

K

Cl

TCO<sub>2</sub>

iCa

Creat/  
eGFR

BUN

GLU

Lac

ePV

CO-Ox

MCHC



## The Modern Critical Care Profile

Prime Plus provides the most clinical value of any blood gas/critical care analyzer by adding essential tests for kidney function (BUN, Creatinine, eGFR), plasma volume (ePV), ionized magnesium (iMg) and MCHC.

### Ionized Magnesium (iMg)

Hypomagnesemia is a frequent finding in critically ill patients.<sup>1</sup> Magnesium therapy guided by real time ionized magnesium monitoring has been shown to improve outcome in these patients.<sup>2</sup>

### Creatinine, eGFR, and BUN

Over 50% of patients admitted to the ICU develop some degree of acute kidney injury.<sup>3</sup> Creatinine, eGFR, and BUN monitoring provides indication of changes in kidney function and helps guide therapy to prevent AKI.

### Estimated Plasma Volume (ePV)

The plasma volume status of a patient is one of the top priorities in evaluating and treating critical illness including CHF, ARDS, AKI, and Sepsis.<sup>4-6</sup>

### Mean Corpuscular Hemoglobin Concentration (MCHC)

Helps differentiate types of anemia.



## Comprehensive tests for triage and treatment

- Basic Metabolic Profile
- Renal panel with Creat/eGFR critical for early AKI detection
- Lactate to identify and guide therapy for hypoxia in sepsis
- Measured Hb and Hct for evaluation of anemia and O<sub>2</sub> transport capability
- ePV for assessment of fluid balance
- Blood gas and CO-Ox for acid-base disturbances and pulmonary function



## Emergency Department Point-Of-Care Testing for Basic Metabolic Profile (BMP) Reduces ED Length of Stay and Improves Patient Outcomes

- Comprehensive point-of-care testing (POCT) including a metabolic panel has been shown to significantly reduce ED LOS.<sup>7,10</sup>
- POCT in the ED can provide results an average of 46 minutes earlier than the central lab.<sup>8</sup>
- POCT at ED triage may help identify critically ill patients and can help improve patient safety.<sup>11</sup>
- POCT has been shown to reduce delays to treatment<sup>4</sup> and ED care time by approximately one hour.<sup>9</sup>
- POCT has been shown to increase early and timely patient discharge from the ED<sup>8,10</sup> — in some cases by 55 minutes<sup>12</sup> — compared to patients tested using the lab.

### References

1. Soliman HM. Development of ionized hypomagnesemia is associated with higher mortality rates. *Crit Care Med* 2003;31(4):1082-7.
2. Wilkes NJ et al. Correction of ionized plasma magnesium during cardiopulmonary bypass reduces the risk of postoperative cardiac arrhythmia. *Anesth and Analg* 2002;95(4) 828-834.
3. Mandelbaum T et al. Outcome of critically ill patients with acute kidney injury using the AKIN criteria. *Crit Care Med* 2011;39(12):2659-2664.
4. Kobayashi M et al. Prognostic Value of Estimated Plasma Volume in Heart Failure in Three Cohort Studies; *Clin Res Cardiol* 2019;108(5): 549-561.
5. Niedermeyer, et al. Calculated Plasma Volume Status Is Associated With Mortality in Acute Respiratory Distress Syndrome. *Critical Care Explorations*: September 2021, V3(9):1-9.
6. Kim HK et al. Prognostic Value of Estimated Plasma Volume Status in Patients with Sepsis. *J Korea Med Sci* 2020;9(37):1-10.
7. Jang JY, et al. Use of a comprehensive metabolic panel point-of-care test to reduce length of stay in the emergency department: A randomized controlled trial. *Ann Emerg Med* 2013;61(2):145-151.
8. Rooney KD et al. Point-of-care testing in the overcrowded emergency department – can it make a difference? *Crit Care* 2014;18:692.
9. Singer AJ et al. Early point-of-care testing at triage reduces care time in stable emergency department patients. *J Emerg Med* 2018;55(2):172-178.
10. Kankaanpää M et al. Use of point-of-care testing and early assessment model reduces length of stay for ambulatory patients in an emergency department. *Scand J Trauma Resusc Emerg Med* 2016;24:125.
11. Abualenain J et al. The effect of point-of-care testing at triage: An observational study in a teaching hospital in Saudi Arabia. *West J Emerg Med* 2018;19(5):884-888.
12. Kankaanpää M et al. Comparison of the use of comprehensive point-of-care test panel to conventional laboratory process in emergency department. *BMC Emerg Med* 2018;18:43.

**nova**<sup>®</sup>  
biomedical  
novabiomedical.com



**Nova Biomedical Headquarters:** 200 Prospect St., Waltham, MA 02454 U.S.A., +1-781-894-0800 800-458-5813, FAX: +1-781-894-5915, Int'l FAX: +1-781-899-0417, e-mail: info@novabio.com  
**Nova Biomedical Australia ANZ Pty. Ltd.:** 5/372 Eastern Valley Way, Chatswood, NSW, 2067, Australia, TEL: +61(0) 2 9417 0193, email: AU-info@novabio.com  
**Nova Biomedical Benelux B.V.:** Korenmolen 22, 5281 PB, Baxtel, The Netherlands, TEL: +31(0)733032701, e-mail: benelux-info@novabio.com  
**Nova Biomedical Brasil:** Rua Massena, 107, Jardim Canadá, Nova Lima - MG, CEP: 34007-746 Brasil, TEL: +55-31-3360-2500, e-mail: BR-info@novabio.com  
**Nova Biomedical Canada, Ltd.:** 17 – 2900 Argentea Road, Mississauga, Ontario L5N 7X9 Canada, TEL: +1-905-567-7700 800-263-5999, FAX: +1-905-567-5496, e-mail: CA-info@novabio.com  
**Nova Biomedical France:** Parc Technopolis - Bât. Sigma 3 Avenue du Canada 91940 Les Ulis Courtaboeuf, France, TEL: +33-1-64 86 11 74, FAX: +33-1-64 46 24 03, e-mail: FR-info@novabio.com  
**Nova Biomedical GmbH, Deutschland:** Hessenring 13 A, Geb. G, 64546 Mörfelden-Walldorf, Germany, TEL: +49-6105 4505-0, FAX: +49-6105 4505-37, e-mail: DE-info@novabio.com  
**Nova Biomedical Iberia, S.L.:** c/Vic 17, Planta 3A 08173 Sant Cugat del Vallès, Barcelona, Spain, TEL: +34 935531173, e-mail: ES-info@novabio.com or PT-info@novabio.com  
**Nova Biomedical Italia S.r.l.:** via Como, 19 - 20045 Lainate (MI), Italy, Tel: +39 02 87070041, Fax: +39 02 87071482, e-mail: IT-info@novabio.com  
**Nova Biomedical K.K., Japan:** Harumi Island Triton Square Office Tower X 7F, 1-8-10 Harumi, Chuo-ku, Tokyo 104-6007, Japan, TEL: 03-5144-4144, FAX: 03-5144-4177, e-mail: jp-info@novabio.com  
**Nova Biomedical New Zealand:** Regus Constellation Drive - Candida Building 4 Level 3/61 Constellation Drive, Rosedale, Auckland, 0630, New Zealand, TEL: +64 800 555 268, email: AU-info@novabio.com  
**Nova Biomedical Schweiz GmbH:** Herostrasse 7, 8048 Zürich, Switzerland, TEL: +41-41-521-6655, FAX: +41-41-521-6656, e-mail: CH-info@novabio.com  
**Nova Biomedical U.K.:** Innovation House, Aston Lane South, Runcorn, Cheshire WA7 3FY United Kingdom, TEL: +44-1928 704040, FAX: +44-1928 796792, e-mail: UK-info@novabio.com